# Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer

> **NCT01145404** · PHASE2 · TERMINATED · sponsor: **National Center for Tumor Diseases, Heidelberg** · enrollment: 76 (estimated)

## Conditions studied

- GastroEsophageal Cancer

## Interventions

- **DRUG:** Lapatinib
- **DRUG:** Lapatinib plus capecitabine

## Key facts

- **NCT ID:** NCT01145404
- **Lead sponsor:** National Center for Tumor Diseases, Heidelberg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06
- **Primary completion:** 2013-02
- **Final completion:** 2013-10
- **Target enrollment:** 76 (ESTIMATED)
- **Why stopped:** Changes of SoC for third line therapy resulting in poor recruitment
- **Last updated:** 2014-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01145404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01145404, "Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01145404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*